Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease
Open accessThe DOI matches its Crossref record; 142 of the 149 references it cites were found in a registry or an index.
Abstract
Approximately 25% of US adults are estimated to have hypertriglyceridemia (triglyceride [TG] level ≥150 mg/dL [≥1.7 mmol/L]). Elevated TG levels are associated with increased cardiovascular disease (CVD) risk, and severe hypertriglyceridemia (TG levels ≥500 mg/dL [≥5.6 mmol/L]) is a well-established risk factor for acute pancreatitis. Plasma TG levels correspond to the sum of the TG content in TG-rich lipoproteins (TRLs; ie, very low-density lipoproteins plus chylomicrons) and their remnants. There remains some uncertainty regarding the direct causal role of TRLs in the progression of atherosclerosis and CVD, with cardiovascular outcome studies of TG-lowering agents, to date, having produced inconsistent results. Although low-density lipoprotein cholesterol (LDL-C) remains the primary treatment target to reduce CVD risk, a number of large-scale epidemiological studies have shown that elevated TG levels are independently associated with increased incidence of cardiovascular events, even in patients treated effectively with statins. Genetic studies have further clarified the causal association between TRLs and CVD. Variants in several key genes involved in TRL metabolism are strongly associated with CVD risk, with the strength of a variant's effect on TG levels correlating with the magnitude of the variant's effect on CVD. TRLs are thought to contribute to the progression of atherosclerosis and CVD via a number of direct and indirect mechanisms. They directly contribute to intimal cholesterol deposition and are also involved in the activation and enhancement of several proinflammatory, proapoptotic, and procoagulant pathways. Evidence suggests that non-high-density lipoprotein cholesterol, the sum of the total cholesterol carried by atherogenic lipoproteins (including LDL, TRL, and TRL remnants), provides a better indication of CVD risk than LDL-C, particularly in patients with hypertriglyceridemia. This article aims to provide an overview of the available epidemiological, clinical, and genetic evidence relating to the atherogenicity of TRLs and their role in the progression of CVD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Proposed pathophysiology of triglyceride-rich lipoproteins in the progression of atherosclerosis. Note: Adapted by permission from Macmillan Publishers Ltd: [Nature Reviews Cardiology] Watts GF, Ooi EM, Chan DC. Demystifying the management of hypertriglyceridaemia. Nat Rev Cardiol. 2013;10(11):648–661,126 Copyright © 2013. Abbreviations: LPL, lipoprotein lipase; TRL, triglyceride-rich lipoproteins; TRL-R, triglyceride-rich lipoprotein remnants.](https://figures.cochat.ai/paper-figures/0257c3040d4b4514b3d59741a7e289ea/triglyceride-rich-lipoproteins-as-a-causal-factor-for-cardiovascular-disease-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Upon entering the arterial intima, these remnants are selectively retained through binding to extracellular matrix proteoglycans, prolonging their residence time in the subendothelial space. This retention facilitates uptake by resident macrophages via scavenger receptors, without requiring the oxidative modification typical of LDL particles.”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Genetic studies and epidemiologic data increasingly implicate remnant lipoproteins as causal contributors to atherogenesis, providing a strong mechanistic and clinical rationale for targeted intervention [8–12].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“The elevated cholesterol content per remnant particle, compared to LDL, amplifies their contribution to lipid accumulation and foam cell formation, key early events in plaque development [17].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423 · cited 1×
“It is also worth noting that LDL-C levels are ordinarily estimated by the Friedewald equation.(116) The Friedewald equation is inapplicable for patients with fasting TG .”
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Antihyperlipidemic and Biochemical Activities of Mcy Protein in Streptozotocin Induced Diabetic Rats
Marella, S., Maddirela, D. R., Badri, K. R., Jyothi Kumar, M. V., & Chippada, A. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373954 · Cited by 5,938
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
(1999) · The Lancet · doi:10.1016/s0140-6736(99)07072-5 · Cited by 3,812 · cited 1×
“The Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardio (GISSI)-Prevenzione Trial showed that in postMI patients, EPA and DHA significantly reduced the risk of reinfarction and death over a 3-year follow-up period.(97) Additionally, in the Japan EPA Lipid Intervention Study (JELIS), the addition o…”
BackgroundESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Cited by
Items 201–236 of 236
Maio, A., & Dowd, F. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64176-4 · Cited by 1
Targeting triglycerides for cardiovascular risk reduction
Maiorca, C., Tramontano, D., Di Costanzo, A., & D’Erasmo, L. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04383-1
“The elevated cholesterol content per remnant particle, compared to LDL, amplifies their contribution to lipid accumulation and foam cell formation, key early events in plaque development [17].”
Genetic and Epigenetic Regulations of Post-prandial Lipemia
Xu, H. (2018) · Current Genetic Medicine Reports · doi:10.1007/s40142-018-0146-9
СУЖДЕНИЕ О ПОДБОРЕ ОПТИМАЛЬНОЙ ОЦЕНКИ РИСКА ИШЕМИЧЕСКОЙ БОЛЕЗНИ СЕРДЦА ДЛЯ ВРАЧА-ЛЕЧЕБНИКА
Volkova, M. S., Lipilkin, P. V., Zigler, G. D., Moiseeva, Y. N., Nedilko, A. V., Nedilko, A. V., & Terpitskaya, T. A. (2018) · В мире научных открытий · doi:10.12731/wsd-2018-4-111-133
Maleki, S., Fesharaki, M. G., & Rowzati, M. (2018) · Iranian Red Crescent Medical Journal · doi:10.5812/ircmj.70692
Ifrim, S., Amălinei, C., Azoicăi, D., Cojocaru, E., Butcovan, D., Ifrim, M., & Matei, M. C. (2017) · The Medical-Surgical Journal
Mitigating Risk Patients With Dyslipidemia
Wright, R. S., & Murphy, J. G. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.07.013
Xu, J., Du, X., Zhang, S., Xiang, Q., Guo, L., Zhu, L., Tan, Y., Fu, Y., Xie, Y., Zhang, M., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-871652/v1
Grundy, S. M. (2018) · Endocrinology · doi:10.1007/978-3-319-27316-7_3-1 · Cited by 1
Solvation Dynamics of a Single Triglyceride as a Function of its Chain LengthPreprint
Sacher, S., & Ray, A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.28.486057
A ATEROSCLEROSE E O INFARTO AGUDO DO MIOCÁRDIO
Couras, P. G. M., Torres, A. C. O., Rodrigues, J. D., Bispo, F. C. D. P., Assunção, R. F. I., Davanço, R. L., Carvalho, A. L. M. D. A., Endres, V. D. S., Franco, K. S. C. P., Taira, L. A., et al. (2022) · RECIMA21 - Revista Científica Multidisciplinar · doi:10.47820/recima21.v3i4.1327
“Tabagismo está relacionado à hipertensão arterial sistêmica, já que possui efeito vasoconstritor, aumentando o risco de lesão endotelial e rompimento das já presentes (MARTELLI, 2014; TOTH, 2016).”
BackgroundKim, H., & Lee, J. K. (2020) · Gazzetta Medica Italiana Archivio per le Scienze Mediche · doi:10.23736/s0393-3660.19.04144-5
Bocharova, O. V., Teplyakova, E. D., Shkurat, T. P., Karantysh, G. V., & Ali, A. H. A. (2022) · Medical Herald of the South of Russia · doi:10.21886/2219-8075-2022-13-2-102-112
Primär genetische Dyslipoproteinämien und Atheroskleroserisiko
Schwab, K. O., & Doerfer, J. (2022) · Springer eBooks · doi:10.1007/978-3-662-63320-5_3
Riesgo aterogénico en la preeclampsia agravada lejos del termino y de aparición tardía
González, J. A. S., Machado, M. G., González, E. Á.-G., & Muñoz, N. L. S. (2023) · Revista de la Federación Centroamericana de Obstetricia y Ginecología · doi:10.37980/im.journal.revcog.20232113
Gilyarevskiy, S. R. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-268
Hypertriglyceridemia in STEC-hemolytic uremic syndrome: does it really matter?
Balestracci, A., & Battaglia, L. M. (2024) · Pediatric Nephrology · doi:10.1007/s00467-024-06458-7
“…of plasminogen activator inhibitor-1 (PAI-1), the major inhibitor of plasminogen activators in the circulation and thereby the principal inhibitor of the fibrinolytic system [1, 3], which would further strengthen the hypercoagulability and vessel occlusion of the STEC-HUS, complicating its course.”
InfluentialRasheid, A. W. (2025) · Jurnal Biologi · doi:10.47134/biology.v2i2.3738
Triglyceride Levels Should be Lowered to Reduce Cardiovascular Risk
Corral, P., & Cobo, A. L. (2025) · Revista Argentina de Cardiología · doi:10.7775/rac.v93.i1.20865
Research Progress of Remnant Cholesterol in Atherosclerotic Cardiovascular Disease
王, 怡. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1551354
Duan, M., Zhang, N., Ma, S., Zhang, X., Shi, K., Gao, T., Yang, H., Ma, X., Cheng, Y., Qu, H., et al. (2025) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2025.108499
Huo, G., Huang, J., Zhang, J., & Zhou, D. (2025) · BMC Neurology · doi:10.1186/s12883-025-04558-x · Cited by 1
Kandy, L. N., Mahendra, J., Jayaraman, S., Retnakaran, R., Jose, J. P., Ramachandran, R., Vijayan, V., Parambath, J., & Divakaran, D. R. (2026) · Indian Journal of Cardiovascular Disease in Women · doi:10.25259/ijcdw_56_2025
Gupta, B. K., Pandey, R., Thapa¹, N., Neupane¹, B., Bhattarai¹, S., & Risal, P. (2026) · Research Square · doi:10.21203/rs.3.rs-9141505/v1
Hypertriglycéridémie postprandiale : signature microARN et insulino-résistance
housseini, R. E. (2019) · theses.fr (ABES) · doi:10.70675/7d24ea93z83a6z478aza78dzaa7adafeb958
Personalised medicine approaches for investigation and application of new biomarkers
Gorenjak, V. (2019) · theses.fr (ABES) · doi:10.70675/f44144aaz4538z45abz9ce9za155e0c2e883 · Cited by 1
Association of Remnant Cholesterol With the Retinal Capillary Plexus
Ding, S., Zhu, X., Yang, K., Wang, Y., Wang, Z. Y., Li, Z., Lian, W., Yan, J., Chen, W. F., Yang, M., et al. (2026) · Translational Vision Science & Technology · doi:10.1167/tvst.15.4.18
“5,6 Extensive previous studies have demonstrated that RC is significantly associated with an increased residual risk of macrovascular diseases such as ASCVD, and this association is independent of LDL-C.”
Liu, J. T., Guan, X., Pang, X., Liu, X., Xin, Z., & Shi, M. (2026) · Medicine · doi:10.1097/md.0000000000048926
Li, Y., Chen, Z., Shang, L., Wang, Y., Liu, X. R., Yang, Y., & He, L. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1770876
“Additionally, RC induces oxidative stress in vascular endothelial cells, reducing nitric oxide bioavailability and impairing endothelial function, thereby promoting metabolic dysfunction (32, 33).”
Katkó, M., Gazdag, A., Szentpéteri, A., Lőrincz, H., Galgoczi, E., Erdei, A., Berta, E., Bodor, M., Nagy, E. V., & Harangi, M. (2026) · Life · doi:10.3390/life16071083
“Triglyceride-rich lipoprotein (TRL) particles are increasingly recognized as important contributors to atherogenesis [48].”
Rethinking triglycerides in the management of atherosclerotic cardiovascular disease
Khanna, S., Bhatt, D. L., Libby, P., & Bhat, A. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag341 · Cited by 1
Modified cardiometabolic index and stroke risk: Evidence from the CHARLS cohort
Wu, X., Chen, S., Lv, T., & Zhou, Z. (2026) · Medicine · doi:10.1097/md.0000000000050148 · Cited by 1
“[42,43] Impaired anti-inflammatory and antioxidant functions of HDL-C may accelerate atherosclerotic progression, [44] consistent with the increased stroke risk observed in this study.”
Metadata
- Authors
- Toth, P.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Toth, Peter
- ORCID
- Toth, Peter
- Venue
- Vascular Health and Risk Management
- Publisher
- Informa UK Limited
- Published
- 2016-05
- Volume
- 12
- Pages
- 171
- ISSN
- 1176-6344 (ISSN-L)
- 1178-2048
- PMC
- PMC4866746
- OpenAlex
- W2345841042
- Cited by
- 237
- References
- 149
- Citations by year
- 2026: 15 · 2025: 22 · 2024: 11 · 2023: 18 · 2022: 27 · 2021: 34 · 2020: 29 · 2019: 22 · 2018: 29 · 2017: 22 · 2016: 8
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Vascular Health and Risk Management (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- triglyceride-rich lipoproteins, hypertriglyceridemia, cardiovascular risk, atherosclerosis, VLDL, chylomicrons, acute pancreatitis, non-HDL cholesterol, genetic variants, statin therapy, pro-inflammatory pathways, LDL cholesterol
- MeSH terms
- Animals, Hypolipidemic Agents, Cardiovascular Diseases, Humans, Lipoproteins, Phenotype, Risk Factors, Triglycerides, Hypertriglyceridemia, Biomarkers, Treatment Outcome, Disease Progression, Risk Assessment, Genetic Predisposition to Disease, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.